Loading company…
Remix Therapeutics develops small-molecule therapies that target RNA processing, with a focus on oncology.
Remix Therapeutics develops RNA-targeted therapies using a small-molecule drug discovery platform, focusing on oncology and previously undruggable targets. Founded in 2018, the company is based in Watertown, US. In January 2024, it raised USD 60 mn in Series B funding led by The Column Group to advance its pipeline, including REM-422.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in